Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Riederer

Showing results (231-240 of 587) with videos related to

Pageof 59
Sort By:
Wiener Zeitschrift Fur Nervenheilkunde Und Deren Grenzgebiete|January 1, 1973
[Biochemical aspects of human behavior]L Ambrozi, W Birkmayer, W Danielczyk, et al.
Annals of Neurology|January 1, 1992
Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's diseaseD Ben-Shachar, G Eshel, P Riederer, et al.
Neurotoxicity Research|June 22, 2006
Strategies for the protection of dopaminergic neurons against neurotoxicityM Gerlach, K L Double, M B Youdim, et al.
Neuroscience Letters|February 11, 1991
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?H Russ, W Mihatsch, M Gerlach, et al.
Pharmacology & Therapeutics|January 1, 1994
Oxidative stress: free radical production in neural degenerationM E Götz, G Künig, P Riederer, et al.
Journal of Psychiatry & Neuroscience : JPN|January 1, 1995
Cholinergic neurotransmission seems not to be involved in depression but possibly in personalityJ Fritze, M Lanczik, E Sofic, et al.
European Journal of Pharmacology|March 29, 1989
[3H]MK-801 binding sites in post-mortem human frontal cortexJ Kornhuber, F Mack-Burkhardt, M E Kornhuber, et al.
Advances in Neurology|January 1, 1987
Terguride: partial dopamine agonist in the treatment of Parkinson's diseaseT Brücke, W Danielczyk, M Simányi, et al.
European Journal of Pharmacology|June 13, 1996
Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridiniumE Koutsilieri, T S Chen, W D Rausch, et al.
Pharmacopsychiatry|May 1, 1990
Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrationsJ Fritze, T Becker, V Ziegler, et al.
Pageof 59

Showing results (231-240 of 587) with videos related to

Sort By:
Pageof 59
Wiener Zeitschrift Fur Nervenheilkunde Und Deren Grenzgebiete|January 1, 1973
[Biochemical aspects of human behavior]L Ambrozi, W Birkmayer, W Danielczyk, et al.
Annals of Neurology|January 1, 1992
Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's diseaseD Ben-Shachar, G Eshel, P Riederer, et al.
Neurotoxicity Research|June 22, 2006
Strategies for the protection of dopaminergic neurons against neurotoxicityM Gerlach, K L Double, M B Youdim, et al.
Neuroscience Letters|February 11, 1991
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?H Russ, W Mihatsch, M Gerlach, et al.
Pharmacology & Therapeutics|January 1, 1994
Oxidative stress: free radical production in neural degenerationM E Götz, G Künig, P Riederer, et al.
Journal of Psychiatry & Neuroscience : JPN|January 1, 1995
Cholinergic neurotransmission seems not to be involved in depression but possibly in personalityJ Fritze, M Lanczik, E Sofic, et al.
European Journal of Pharmacology|March 29, 1989
[3H]MK-801 binding sites in post-mortem human frontal cortexJ Kornhuber, F Mack-Burkhardt, M E Kornhuber, et al.
Advances in Neurology|January 1, 1987
Terguride: partial dopamine agonist in the treatment of Parkinson's diseaseT Brücke, W Danielczyk, M Simányi, et al.
European Journal of Pharmacology|June 13, 1996
Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridiniumE Koutsilieri, T S Chen, W D Rausch, et al.
Pharmacopsychiatry|May 1, 1990
Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrationsJ Fritze, T Becker, V Ziegler, et al.
Pageof 59